Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
boston blog main
boston top stories
12
×
life sciences
national blog main
clinical trials
national top stories
boston
fda
san francisco blog main
deals
eli lilly
roche
san francisco top stories
alnylam pharmaceuticals
amgen
blueprint medicines
cancer
cancer drugs
new york blog main
novartis
rare disease drugs
san diego blog main
alexion pharmaceuticals
avapritinib
dyne therapeutics
europe blog main
genentech
hepatitis b
indiana blog main
indiana top stories
investing
medullary thyroid cancer
myotonic dystrophy type 1
new york top stories
non-small cell lung cancer
pralsetinib
raleigh-durham blog main
raleigh-durham top stories
rna interference
What
drug
12
×
medicines
12
×
ipo
new
cancer
fda
genetic
approval
company
disease
lead
million
muscle
research
therapeutics
biotech
blueprint
brings
candidate
deal
diseases
dyne
hepatitis
pharma
pharmaceuticals
raised
rare
ready
ret
roche
targets
team
acquire
address
adds
ago
agreed
alliance
alternative
amgen
Language
unset
Current search:
biotech
×
drug
×
medicines
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines